VERTEX PHARMACEUTICALS INC / MA Accounts Payable
VERTEX PHARMACEUTICALS INC / MA (VRTX) had Accounts Payable of $429.50 million as of 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Current › Accounts Payable and Accrued Liabilities, Current
us-gaap:AccountsPayableCurrent · last filed 2026-08-04
- 2026-06-30: Accounts Payable, Current $429.50M.
- 2026-03-31: Accounts Payable, Current $489.30M.
- 2025-12-31: Accounts Payable, Current $461.70M.
- 2025-09-30: Accounts Payable, Current $420.30M.
| Period end | Accounts Payable, Current | Accounts Payable, Current as first filed |
|---|---|---|
| 2026-06-30 | $429.50M 10-Q · filed 2026-08-04 | |
| 2026-03-31 | $489.30M 10-Q · filed 2026-05-05 | |
| 2025-12-31 | $461.70M 10-Q · filed 2026-08-04 | |
| 2025-09-30 | $420.30M 10-Q · filed 2025-11-04 | |
| 2025-06-30 | $442.30M 10-Q · filed 2025-08-05 | |
| 2025-03-31 | $445.00M 10-Q · filed 2025-05-06 | |
| 2024-12-31 | $413.00M 10-K · filed 2026-02-13 | |
| 2024-09-30 | $395.80M 10-Q · filed 2024-11-05 | |
| 2024-06-30 | $327.90M 10-Q · filed 2024-08-02 | |
| 2024-03-31 | $351.40M 10-Q · filed 2024-05-07 | |
| 2023-12-31 | $364.90M 10-K · filed 2025-02-13 | |
| 2023-09-30 | $375.90M 10-Q · filed 2023-11-07 | |
| 2023-06-30 | $363.00M 10-Q · filed 2023-08-02 | |
| 2023-03-31 | $323.20M 10-Q · filed 2023-05-02 | |
| 2022-12-31 | $303.90M 10-K · filed 2024-02-15 | |
| 2022-09-30 | $126.90M 10-Q · filed 2022-10-28 | |
| 2022-06-30 | $198.00M 10-Q · filed 2022-08-05 | |
| 2022-03-31 | $173.60M 10-Q · filed 2022-05-06 | |
| 2021-12-31 | $195.00M 10-K · filed 2023-02-10 | |
| 2021-09-30 | $127.86M 10-Q · filed 2021-11-03 | |
| 2021-06-30 | $127.53M 10-Q · filed 2021-07-30 | |
| 2021-03-31 | $127.84M 10-Q · filed 2021-04-30 | |
| 2020-12-31 | $155.10M 10-K · filed 2022-02-09 | $155.14M 10-K · filed 2021-02-11 |
| 2020-09-30 | $107.79M 10-Q · filed 2020-10-30 | |
| 2020-06-30 | $101.45M 10-Q · filed 2020-07-31 | |
| 2020-03-31 | $100.70M 10-Q · filed 2020-05-01 | |
| 2019-12-31 | $87.61M 10-K · filed 2021-02-11 | |
| 2019-09-30 | $92.53M 10-Q · filed 2019-10-31 | |
| 2019-06-30 | $77.05M 10-Q · filed 2019-08-01 | |
| 2019-03-31 | $82.26M 10-Q · filed 2019-05-01 | |
| 2018-12-31 | $110.99M 10-K · filed 2020-02-13 | |
| 2018-09-30 | $92.15M 10-Q · filed 2018-10-25 | |
| 2018-06-30 | $83.03M 10-Q · filed 2018-07-26 | |
| 2018-03-31 | $74.06M 10-Q · filed 2018-04-27 | |
| 2017-12-31 | $73.99M 10-K · filed 2019-02-13 | |
| 2017-09-30 | $77.14M 10-Q · filed 2017-10-30 | |
| 2017-06-30 | $75.94M 10-Q · filed 2017-07-28 | |
| 2017-03-31 | $63.15M 10-Q · filed 2017-04-28 | |
| 2016-12-31 | $61.45M 10-K · filed 2018-02-15 | |
| 2016-09-30 | $50.91M 10-Q · filed 2016-10-31 | |
| 2016-06-30 | $51.30M 10-Q · filed 2016-08-01 | |
| 2016-03-31 | $75.22M 10-Q · filed 2016-05-03 | |
| 2015-12-31 | $74.94M 10-K · filed 2017-02-23 | |
| 2015-09-30 | $78.90M 10-Q · filed 2015-10-30 | |
| 2015-06-30 | $72.70M 10-Q · filed 2015-08-04 | |
| 2015-03-31 | $43.52M 10-Q · filed 2015-05-04 | |
| 2014-12-31 | $71.19M 10-K · filed 2016-02-16 | |
| 2014-09-30 | $38.47M 10-Q · filed 2014-11-06 | |
| 2014-06-30 | $55.36M 10-Q · filed 2014-07-31 | |
| 2014-03-31 | $49.57M 10-Q · filed 2014-05-05 | |
| 2013-12-31 | $49.33M 10-K · filed 2015-02-13 | |
| 2013-09-30 | $51.53M 10-Q · filed 2013-11-07 | |
| 2013-06-30 | $48.57M 10-Q · filed 2013-08-02 | |
| 2013-03-31 | $59.63M 10-Q · filed 2013-05-08 | |
| 2012-12-31 | $101.29M 10-K · filed 2014-02-11 | |
| 2012-09-30 | $83.73M 10-Q · filed 2012-11-06 | |
| 2012-06-30 | $59.35M 10-Q · filed 2012-08-08 | |
| 2012-03-31 | $73.23M 10-Q · filed 2012-05-10 | |
| 2011-12-31 | $74.64M 10-K · filed 2013-03-01 | |
| 2011-09-30 | $49.25M 10-Q · filed 2011-11-03 | |
| 2011-06-30 | $67.28M 10-Q · filed 2011-08-09 | |
| 2011-03-31 | $34.88M 10-Q · filed 2011-05-06 | |
| 2010-12-31 | $35.85M 10-K · filed 2012-02-22 | |
| 2010-09-30 | $24.64M 10-Q · filed 2010-10-28 | |
| 2010-06-30 | $46.49M 10-Q · filed 2010-08-03 | |
| 2010-03-31 | $29.12M 10-Q · filed 2010-05-03 | |
| 2009-12-31 | $36.99M 10-K · filed 2011-02-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |